Effectiveness of Spironolactone in Reducing Osteoporosis and Future Fracture Risk in Middle-Aged and Elderly Hypertensive Patients

References

• Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med. 2017;167(3):ITC17–ITC32. doi:10.7326/AITC201708010
   PubMed Web of Science ®Google Scholar
• Cho HW, Jin HS, Eom YB. FGFRL1 and FGF genes are associated with height, hypertension, and osteoporosis. PLoS One. 2022;17(8):e0273237. doi:10.1371/journal.pone.0273237
   PubMedGoogle Scholar
• Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–450. doi:10.1161/CIRCULATIONAHA.115.018912
   PubMed Web of Science ®Google Scholar
• Xiao PL, Cui AY, Hsu CJ, et al. Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int. 2022;33(10):2137–2153. doi:10.1007/s00198-022-06454-3
   PubMed Web of Science ®Google Scholar
• Hurley DL, Khosla S. Update on primary osteoporosis. Mayo Clin Proc. 1997;72(10):943–949. doi:10.1016/S0025-6196(11)63367-3
   PubMed Web of Science ®Google Scholar
• Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):2549–2558. doi:10.1016/S0140-6736(17)32478-9
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Richterich JP, Stanga Z, et al. Osteoporosis, diabetes, and hypertension are major risk factors for mortality in older adults: an intermediate report on a prospective survey of 1467 community-dwelling elderly healthy pensioners in Switzerland. BMC Geriatr. 2018;18(1):115. doi:10.1186/s12877-018-0809-0
   PubMedGoogle Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–1733. doi:10.1007/s00198-006-0172-4
   PubMed Web of Science ®Google Scholar
• Mo C, Ke J, Zhao D, et al. Role of the renin-angiotensin-aldosterone system in bone metabolism. J Bone Miner Metab. 2020;38(6):772–779. doi:10.1007/s00774-020-01132-y
   PubMed Web of Science ®Google Scholar
• Kao YT, Huang CY, Fang YA, et al. The association between renin angiotensin aldosterone system blockers and future osteoporotic fractures in a hypertensive population - A population-based cohort study in Taiwan. Int J Cardiol. 2020;305:147–153. doi:10.1016/j.ijcard.2019.12.069
   PubMed Web of Science ®Google Scholar
• Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287(5):H2023–6. doi:10.1152/ajpheart.00477.2004
   PubMed Web of Science ®Google Scholar
• Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669–683. doi:10.1056/NEJMoa055218
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Interven Trial Res. 1996;348(9041):1535–1541. doi:10.1016/s0140-6736(96)07088-2
   Google Scholar
• Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol. 1989;30(4):435–442. doi:10.1111/j.1365-2265.1989.tb00443.x
   PubMed Web of Science ®Google Scholar
• Gao X, Yamazaki Y, Tezuka Y, et al. The crosstalk between aldosterone and calcium metabolism in primary aldosteronism: a possible calcium metabolism-associated aberrant ”neoplastic” steroidogenesis in adrenals. J Steroid Biochem Mol Biol. 2019;193:105434. doi:10.1016/j.jsbmb.2019.105434
   PubMed Web of Science ®Google Scholar
• Wang A, Wang Y, Liu H, et al. Bone and mineral metabolism in patients with primary aldosteronism: a systematic review and meta-analysis. Front Endocrinol. 2022;13:1027841. doi:10.3389/fendo.2022.1027841
   PubMed Web of Science ®Google Scholar
• Salcuni AS, Palmieri S, Carnevale V, et al. Bone involvement in aldosteronism. J Bone Miner Res. 2012;27(10):2217–2222. doi:10.1002/jbmr.1660
   PubMed Web of Science ®Google Scholar
• Song S, Cai X, Hu J, et al. Correlation between plasma aldosterone concentration and bone mineral density in middle-aged and elderly hypertensive patients: potential impact on osteoporosis and future fracture risk. Front Endocrinol. 2024;15(1373862). doi:10.3389/fendo.2024.1373862
   Google Scholar
• Batterink J, Stabler SN, Tejani AM, et al. Spironolactone for hypertension. Cochrane Database Syst Rev. 2010;8:CD008169. doi:10.1002/14651858.CD008169.pub2
   Google Scholar
• Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111(7):871–878. doi:10.1161/01.CIR.0000155621.10213.06
   PubMed Web of Science ®Google Scholar
• Carbone LD, Cross JD, Raza SH, et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol. 2008;52(2):135–138. doi:10.1016/j.jacc.2008.03.039
   PubMed Web of Science ®Google Scholar
• Cai X, Song S, Hu J, et al. Body roundness index improves the predictive value of cardiovascular disease risk in hypertensive patients with obstructive sleep apnea: a cohort study. Clin Exp Hypertens. 2023;45(1):2259132. doi:10.1080/10641963.2023.2259132
   PubMed Web of Science ®Google Scholar
• Hu J, Cai X, Zhu Q, et al. Relationship between plasma aldosterone concentrations and non-alcoholic fatty liver disease diagnosis in patients with hypertension: a retrospective cohort study. Diabetes Metab Syndr Obes. 2023;16:1625–1636. doi:10.2147/DMSO.S408722
   PubMed Web of Science ®Google Scholar
• Cai X, Song S, Hu J, et al. Author Correction: association of the trajectory of plasma aldosterone concentration with the risk of cardiovascular disease in patients with hypertension: a cohort study. Sci Rep. 2024;14(1):9827. doi:10.1038/s41598-024-60563-z
   PubMed Web of Science ®Google Scholar
• Chen HY, Ma KY, Hsieh PL, et al. Long-term effects of antihypertensive drug use and new-onset osteoporotic fracture in elderly patients: a population-based longitudinal cohort study. Chin Med J. 2016;129(24):2907–2912. doi:10.4103/0366-6999.195472
   PubMed Web of Science ®Google Scholar
• Wen Z, Li Y, Xu L, et al. Triglyceride glucose-body mass index is a reliable indicator of bone mineral density and risk of osteoporotic fracture in middle-aged and elderly nondiabetic Chinese individuals. J Clin Med. 2022;11(19):5694. doi:10.3390/jcm11195694
   PubMed Web of Science ®Google Scholar
• Ma H, Cai X, Hu J, et al. Association of systemic inflammatory response index with bone mineral density, osteoporosis, and future fracture risk in elderly hypertensive patients. Postgrad Med. 2024;16:1–11. doi:10.1080/00325481.2024.2354158
   Google Scholar
• Wang L, Jiang J, Li Y, et al. Global trends and hotspots in research on osteoporosis rehabilitation: A bibliometric study and visualization analysis. Front Public Health. 2022;10:1022035. doi:10.3389/fpubh.2022.1022035
   PubMed Web of Science ®Google Scholar
• Watts NB, Camacho PM, Lewiecki EM, et al. American association of clinical endocrinologists/American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal Osteoporosis—2020 Update. Endocr Pract. 2021;27(4):379–380. doi:10.1016/j.eprac.2021.02.001
   PubMed Web of Science ®Google Scholar
• Tang Y, Wang S, Yi Q, et al. High-density lipoprotein cholesterol is negatively correlated with bone mineral density and has potential predictive value for bone loss. Lipids Health Dis. 2021;20(1):75. doi:10.1186/s12944-021-01497-7
   PubMed Web of Science ®Google Scholar
• Lonjon G, Porcher R, Ergina P, et al. Potential pitfalls of reporting and bias in observational studies with propensity score analysis assessing a surgical procedure: a methodological systematic review. Ann Surg. 2017;265(5):901–909. doi:10.1097/SLA.0000000000001797
   PubMed Web of Science ®Google Scholar
• Austin PC. A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res. 2011;46(1):119–151. doi:10.1080/00273171.2011.540480
   PubMed Web of Science ®Google Scholar
• Gu WJ, Duan XJ, Liu XZ, et al. Association of magnesium sulfate use with mortality in critically ill patients with sepsis: a retrospective propensity score-matched cohort study. Br J Anaesth. 2023;131(5):861–870. doi:10.1016/j.bja.2023.08.005
   PubMed Web of Science ®Google Scholar
• Rossi E, Sani C, Perazzoli F, et al. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8(9):884–893. doi:10.1016/0895-7061(95)00182-O
   PubMed Web of Science ®Google Scholar
• Pilz S, Kienreich K, Drechsler C, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012;97(1):E75–9. doi:10.1210/jc.2011-2183
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang C, Ye L, et al. Factors affecting parathyroid hormone levels in different types of primary aldosteronism. Clin Endocrinol. 2016;85(2):267–274. doi:10.1111/cen.12981
   PubMed Web of Science ®Google Scholar
• Ceccoli L, Ronconi V, Giovannini L, et al. Bone health and aldosterone excess. Osteoporos Int. 2013;24(11):2801–2807. doi:10.1007/s00198-013-2399-1
   PubMed Web of Science ®Google Scholar
• Law PH, Sun Y, Bhattacharya SK, et al. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol. 2005;46(1):142–146. doi:10.1016/j.jacc.2005.03.055
   PubMed Web of Science ®Google Scholar
• Runyan AL, Chhokar VS, Sun Y, et al. Bone loss in rats with aldosteronism. Am J Med Sci. 2005;330(1):1–7. doi:10.1097/00000441-200507000-00001
   PubMed Web of Science ®Google Scholar
• Beldhuis IE, Myhre PL, Bristow M, et al. Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function. J Am Coll Cardiol. 2021;77(9):1211–1221. doi:10.1016/j.jacc.2020.12.057
   PubMed Web of Science ®Google Scholar
• Tsujimoto T, Kajio H. Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension. J Am Heart Assoc. 2020;9(23):e018827. doi:10.1161/JAHA.120.018827
   PubMed Web of Science ®Google Scholar
• Cai X, Li N. Association between use of spironolactone and risk of stroke in hypertensive patients: a cohort study. Pharmaceuticals. 2022;16(1):57. doi:10.3390/ph16010057
   Web of Science ®Google Scholar
• Altieri B, Muscogiuri G, Paschou SA, et al. Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. Endocrine. 2018;62(3):506–516. doi:10.1007/s12020-018-1696-z
   PubMed Web of Science ®Google Scholar
• Seki K, Nagasaki M, Yoshino T, et al. Radiographical Diagnostic Evaluation of Mandibular Cortical Index Classification and Mandibular Cortical Width in Female Patients Prescribed Antiosteoporosis Medication: A Retrospective Cohort Study. Diagnostics (Basel). 2024;14(10):1009. doi:10.3390/diagnostics14101009
   PubMedGoogle Scholar
• Alemany M. The roles of androgens in humans: biology, metabolic regulation and health. Int J Mol Sci. 2022;23(19):11952. doi:10.3390/ijms231911952
   PubMed Web of Science ®Google Scholar
• Josse RG.Prevention and management of osteoporosis: consensus statements from the scientific advisory board of the osteoporosis society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women. CMAJ. 1996;155(7):929–934.
   PubMed Web of Science ®Google Scholar
• Bansal N, Katz R, de Boer IH, et al. Influence of estrogen therapy on calcium, phosphorus, and other regulatory hormones in postmenopausal women: the mesa study. J Clin Endocrinol Metab. 2013;98(12):4890–4898. doi:10.1210/jc.2013-2286
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of postmenopausal osteoporosis. Rev Endocr Metab Disord. 2001;2(1):5–12. doi:10.1023/a:1010074422268
   PubMedGoogle Scholar
• Liu Y, Zhou L, Liu Z, et al. Higher blood urea nitrogen and urinary calcium: new risk factors for diabetes mellitus in primary aldosteronism patients. Front Endocrinol. 2020;11:23. doi:10.3389/fendo.2020.00023
   PubMedGoogle Scholar
• Bayomy O, Zaheer S, Williams JS, et al. Disentangling the relationships between the renin-angiotensin-aldosterone system, calcium physiology, and risk for kidney stones. J Clin Endocrinol Metab. 2020;105(6):1937–1946. doi:10.1210/clinem/dgaa123
   PubMed Web of Science ®Google Scholar
• Xue B, Johnson AK, Hay M. Sex differences in angiotensin II- and aldosterone-induced hypertension: the central protective effects of estrogen. Am J Physiol Regul Integr Comp Physiol. 2013;305(5):R459–63. doi:10.1152/ajpregu.00222.2013
   PubMed Web of Science ®Google Scholar
• Olatunji LA, Adeyanju OA, Michael OS, et al. Ameliorative effect of low-dose spironolactone on obesity and insulin resistance is through replenishment of estrogen in ovariectomized rats. Can J Physiol Pharmacol. 2019;97(1):65–74. doi:10.1139/cjpp-2018-0416
   PubMed Web of Science ®Google Scholar
• Büssemaker E, Hillebrand U, Hausberg M, et al. Pathogenesis of hypertension: interactions among sodium, potassium, and aldosterone. Am J Kidney Dis. 2010;55(6):1111–1120. doi:10.1053/j.ajkd.2009.12.022
   PubMed Web of Science ®Google Scholar
• Lemann J, Pleuss JA, Gray RW, et al. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. Kidney Int. 1991;39(5):973–983. doi:10.1038/ki.1991.123
   PubMed Web of Science ®Google Scholar
• Bushinsky DA, Gavrilov K, Chabala JM, et al. Effect of metabolic acidosis on the potassium content of bone. J Bone Miner Res. 1997;12(10):1664–1671. doi:10.1359/jbmr.1997.12.10.1664
   PubMed Web of Science ®Google Scholar